Formulary Committee Membership Will Be Scrutinized By OIG, Attorney Says
Executive Summary
Physicians who sit on formulary committees may be a focus of heightened scrutiny under the HHS Office of the Inspector General's compliance guide due to possible conflict-of-interest issues
You may also be interested in...
Drug Manufacturer Education Grants To Purchasers May Be Kickback, IG Says
Education and research grants to purchasers from pharmaceutical manufacturers may violate the anti-kickback statute, the HHS Inspector General's compliance guide contends
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials